Skip to main content
Premium Trial:

Request an Annual Quote

Correction: Aug 16, 2004

Premium

In the 08-09-04 issue of BioInform, the article, “With Bayer Deal Gone, Lion’s Revenues Set to Continue Sliding; Cost Cutting Expected,” contained several errors. The company’s current products are SRS and Lion Target Engine. Lion no longer sells Lion Discovery Center. In addition, the article reported that Lion’s “order backlog” has been improving instead of its “order pipeline.”

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.